Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer

Yoichi Nakanishi, Koichi Takayama, Koichi Takano, Kohji Inoue, Shin'ichi Osaki, Hiroshi Wataya, Youichi Takaki, Takahiro Minami, Masayuki Kawasaki, Nobuyuki Hara

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Cisplatin and irinotecan are reported to act synergistically. The authors have conducted a phase II trial combining cisplatin and irinotecan in patients with refractory lung cancer to evaluate the activity and safety of the regimen. Twenty-one patients, who had not responded to prior platinum- based chemotherapy, were entered into the study. Both cisplatin (30 mg/m2) and irinotecan (60 mg/m2) were administrated on days 1, 8, and 15, and the regimen was repeated every 28 days. There were six partial responses, and the response rate was 29% (95% confidence interval, 11.3%-52.2%). The median survival time of all patients was 32 weeks, and 1-year and 2-year survival rates were 43% and 11%, respectively. Major toxicities were hematologic; leukopenia of grades 3 and 4 developed in 43% patients, anemia developed in 38%, and thrombocytopenia developed in 19%. One notable nonhematologic toxicity was diarrhea; which was grade 3 in 38%. The weekly chemotherapy combining cisplatin and irinotecan was active against lung cancer, which is refractory to platinum-based chemotherapy. However, skips of drag administration or dose reduction were necessary in 76% patients during two courses of planned administration, though the ratio of actual dose to scheduled dose was 81%. Dose modification would be necessary to yield better results by this weekly chemotherapy.

Original languageEnglish
Pages (from-to)399-402
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number4
DOIs
Publication statusPublished - Aug 1999

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Nakanishi, Y., Takayama, K., Takano, K., Inoue, K., Osaki, S., Wataya, H., Takaki, Y., Minami, T., Kawasaki, M., & Hara, N. (1999). Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 22(4), 399-402. https://doi.org/10.1097/00000421-199908000-00016